“So Joanne, in terms of kind of net interest expense for the year, we're forecasting a few hundred million dollars there.”

In context

“the bottom line. One of the challenges here, Joanne, is obviously FX, but they've actually -- this group has actually driven absolute dollar profit growth in the business. So I think they've figured out how to do this really well, not just with portfolios, but also channels and integrating that. It is a very unique model. And I think the team have done a really good job at understanding it. From a geography perspective, I mean, in my opening comments, a lot of growth in Southeast Asia, a lot of growth in Latin America for us and great growth in India, too. As you know, we've got a large business in India there, too. So I think it's working very well. And I think it's very sustainable, too, given the dynamics of these markets. Regarding your question on interest... Robert Funck: Yes. So Joanne, in terms of kind of net interest expense for the year, we're forecasting a few hundred million dollars there. And then you had a question on share buybacks. As you know, historically, we do buybacks to offset dilution. And so we did some buybacks in the first quarter, again, a few hundred million dollars' worth of buybacks. Scott Leinenweber: Operator, we'll take 1 -- go ahead. Operator: Our next question will come from Danielle Antalffy from UBS. Danielle Antalffy: Just a question on specifically 2 components of the Structural Heart business. The first being MitraClip. Robert, just curious about what you're seeing in that market. That was a market that was severely impacted by both COVID mortality and hospital staffing constraints. Just curious about where you think we are in the recovery specifically in that market? You did seem to put up another decent growth quarter this quarter. And then”